康乃德生物医药Rademikibart在长达52周的特应性皮炎3期研究中展现快速且持久的疗效

美股速递
Mar 30

康乃德生物医药宣布,其核心候选药物Rademikibart在针对中重度特应性皮炎患者开展的3期临床研究中,展现出快速起效且持久的治疗效果,疗效数据持续至第52周。

研究结果显示,Rademikibart能够显著改善患者的皮损严重程度和瘙痒症状。其疗效在治疗初期便迅速显现,并在此后长达一年的观察期内得以稳定维持,凸显了该药物在长期疾病管理中的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10